Key facts
- Raidium’s last known valuation is $55.6M (Nov 2024).
- It has raised $18.2M; the latest was Seed Round ($1.2M) in Sep 2025.
- Notable investors include European Innovation Council, StartX (US), La French Tech, Founders Future, Newfund Management — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Raidium
- ·The full record, as it builds
Funding rounds
No funding rounds for Raidium are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Raidium
Developer of a radiology-augmented technology designed to tackle the complexity of precision medicine. The company utilizes deep learning algorithms for the analysis of medical imaging data and develops a radiology console that brings artificial intelligence assistance directly to the radiologist's workflow via a diagnosis suggestion interface, enabling customers' access to imaging with a focus on screening, allowing earlier management of potential lethal diseases such as cancer, cardiovascular or metabolic pathologies.
- Sector
- Healthcare
- HQ
- Paris, France
- Employees
- 39
- Website
- raidium.eu/
- Ownership
- Privately Held (backing)
Raidium doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Raidium shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Raidium in its N-PORT filings yet. We sweep new filings monthly.